Deborah Garza is co-chair of the firm’s Antitrust and Competition Law Practice Group. With more than 30 years of experience in both the private and public sectors, Ms. Garza has been involved in some of the largest antitrust matters in the last thirty years, including the merger of Exxon and Mobil, the U.S. Government’s suit against Microsoft, the USFL suit against the NFL, and many other litigation and regulatory matters on behalf of Fortune 500 companies. Ms. Garza joined Covington in 2009 from the Justice Department, where she served as Acting Assistant Attorney General in charge of the Antitrust Division. From May 2007 through November 2008, Ms. Garza was Deputy Assistant Attorney General for Regulatory Affairs, overseeing matters in the telecommunications, transportation, energy, health care, agricultural, insurance, broadcast radio, real estate, and other industries. During two prior tours of service during the 1980s, Ms. Garza served as a Special Assistant and as Chief of Staff and Counselor to the Assistant Attorney General in charge of the Antitrust Division. In 2004, Ms. Garza was appointed by President George W. Bush to chair the Antitrust Modernization Commission (“AMC”), a bi-partisan blue-ribbon panel created by Congress to study and report to the President and Congress on the state of antitrust enforcement in the United States. Ms. Garza has been a leader in the Antitrust Section of the American Bar Association. In addition, in 2005, she helped found the Diversity Network, a collaboration of Washington, DC, law firms to provide networking opportunities and access to community leaders for lawyers of diverse backgrounds.
49
Yesterday, the Antitrust Division of the Department of Justice (“DOJ”) announced that it has settled its lawsuit against ValueAct Capital Management L.P. (“ValueAct”) for violating the Hart- Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”). The settlement is noteworthy for two (...)
60
The Federal Trade Commission has brought its first suit alleging anticompetitive conduct in connection with the prosecution and settlement of pharmaceutical patent litigation since the Supreme Court’s June 2013 decision in FTC v. Actavis. Although two commissioners dissented from the decision to (...)
46
Yesterday, the influential Court of Appeals for the Seventh Circuit, sitting en banc, held that foreign anticompetitive conduct can be regulated by U.S. antitrust law if it has “a reasonably proximate causal nexus” with an injury to a U.S. purchaser. The Seventh Circuit explicitly rejected the (...)
54
On July 7, 2011, the Federal Trade Commission and the Department of Justice (“the Agencies”) announced significant changes to the form and accompanying materials that companies must submit when reporting transactions under the Hart-Scott-Rodino Antitrust Improvements Act (“HSR Act”). Although the (...)
64
Last week, the U.S. Justice Department (“DOJ”) and Federal Trade Commission (“FTC”) (together, the “Agencies”) issued revised Horizontal Merger Guidelines (the “Guidelines”) describing how the Agencies seek to determine whether a merger of competing companies will substantially lessen competition. The (...)
55
In the latest development in the Federal Trade Commission’s efforts to challenge Hatch-Waxman patent litigation settlements, earlier this week a federal district court in Pennsylvania denied in part defendants’ motions to dismiss antitrust complaints challenging a series of such settlements. The (...)
55
The Federal Trade Commission (“FTC”) has announced new monetary thresholds for the Hart-Scott-Rodino (“HSR”) Act effective February 22, 2010. See 75 Fed. Reg. 3468 (Jan. 21, 2010). The new thresholds will be approximately 3% lower than those currently in effect. For example, the minimum (...)
Price
€35.00
Women & Antitrust - Voices from the Field, Vol. II
19 avenue Jean Aicard
75011 Paris, France
106 West 32nd Street, Suite 149
New York, NY, 10001, USA
563 Chiswick High Road
W4 3AY London, UK
